Bavarian Nordic A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BAVA.CO research report →
About the company
Hellerup, Denmark-based Bavarian Nordic A/S, founded in 1992, specializes in the research, production, and global distribution of vital, life-saving vaccines. The company's commercialized offerings include non-replicating vaccines for smallpox and monkeypox, marketed as IMVAMUNE, IMVANEX, and JYNNEOS. Additionally, their portfolio features Rabipur/RabAvert for rabies prevention, Encepur for tick-borne encephalitis, and MVABEA, an Ebola vaccine.
- CEO
- Paul John Chaplin
- IPO
- 2000
- Employees
- 1,645
- HQ
- Hellerup, DK
Price Chart
- Market Cap
- $13.73B
- P/E
- 12.19
- P/S
- 2.32
- P/B
- 1.08
- EV/EBITDA
- 5.86
- Div Yield
- 0.00%
- Gross Margin
- 47.40%
- Op Margin
- 25.36%
- Net Margin
- 19.83%
- ROE
- 9.25%
- ROIC
- 8.35%
- Revenue
- $6.17B · 7.96%
- Net Income
- $1.38B · 39.21%
- EPS
- $17.63 · 39.81%
- Op Income
- $920.78M
- FCF YoY
- 859.83%
- 52W High
- $244.80
- 52W Low
- $165.80
- 50D MA
- $188.27
- 200D MA
- $198.94
- Beta
- 0.96
- Avg Volume
- 243.88K
Get TickerSpark's AI analysis on BAVA.CO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BAVA.CO coverage
Recent articles, reports, and earnings notes.
No research on BAVA.CO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BAVA.CO report →Similar companies
Peers in the same neighborhood.